MétaCan
Menu
Back to cohort
Record W4391168380 · doi:10.1186/s13063-023-07828-6

Detailed statistical analysis plan for ALBINO: effect of Allopurinol in addition to hypothermia for hypoxic-ischemic Brain Injury on Neurocognitive Outcome — a blinded randomized placebo-controlled parallel group multicenter trial for superiority (phase III)

2024· article· en· W4391168380 on OpenAlexfundno aff
Corinna Engel, Mario Rüdiger, Manon J.N.L. Benders, Frank van Bel, Karel Allegaert, Gunnar Naulaers, Dirk Bassler, Katrin Klebermaß-Schrehof, Máximo Vento, Ana Vilan, Mari Falck, Isabella Mauro, Marjo Metsäranta, Sampsa Vanhatalo, Jan Mazela, Tuuli Metsvaht, Roselinda van der Vlught, Axel R. Franz, Christian F. Poets, Hercília Guimarães, Tom Stiri, Luigi Cattarossi, Cees K. W. van Veldhuizen, Christian A. Maiwald, Iris Bergmann, Monika Weiß, Andreas Eichhorn, Michael Raubuch, Birgit Schuler, Bas Laméris, Thirza van Ramshorst, Tirol Kliniken, Johannes Brandner, Marie Tackoen, R. Reibel, Mari‐Liis Ilmoja, Pille Saik, Ruth Käär, Pille Andresson, M. Schloesser, Carl Gustav Carus, Stefan Winkler, Thomas Hoehn, Norbert Teig, Michael Schroth, Christoph Fusch, Ulrich Thomé, Harald Ehrhardt, Ancona Virgilio Carnielli, Marcello Napolitano, Francesca Faldini, Bambini “V.Buzzi”, Milano Gianluca Lista, Mario Barbarini, Laura Pagani, Emmanuele Mastretta, Giovanni Vento, Monica Fumagalli, Mirjam M. van Weissenbruch, H. L. M. van Straaten, Kim V. Annink, Jeroen Dudink, Jan Derks, Inge P. de Boer, Clemens B. Meijssen, Timo R. de Haan, Linda G. van Rooij, Jacqueline L. van Hillegersberg, Minouche van Dongen, Koen P. Dijkman, Marlies A. van Houten, Sophie R. D. van der Schoor, Moritz Schneider, Eirik Nestaas, Britt Nakstad, Lukas Karpinski, Ewa Gulczyńska, Cláudia Ferraz, Almerinda Pereira, Rosalina Barroso, Mendes da Graça, Teresa Tomé, Filomena Pinto, Juan Martínez Rodilla, Maria Luz.Couce Pico, José Suazo, Eva Valverde, José Ramón Fernández Lorenzo, Héctor Boix, Francisco Jiménez Parrilla, Dorotea Blanco, Begoña Loureiro, María Teresa Moral‐Pumarega, Julia Maletzki, Claudia Knöepfli, Cornelia Hagmann, Michael Kleber, Martin Stocker, Thomas Riedel

Bibliographic record

VenueTrials · 2024
Typearticle
Languageen
FieldMedicine
TopicNeonatal and fetal brain pathology
Canadian institutionsnot available
FundersUniversitätsklinikum TübingenHorizon 2020 Framework ProgrammeSykehuset i VestfoldAkershus UniversitetssykehusUniwersytet Medyczny im. Karola Marcinkowskiego w PoznaniuMedizinische Universität GrazKarl-Franzens-Universität GrazUniversität UlmRuhr-Universität BochumWarszawski Uniwersytet MedycznyHospital for Sick ChildrenGoethe-Universität Frankfurt am MainUniversitair Medisch Centrum UtrechtSt. Antonius ZiekenhuisUniwersytet Medyczny im. Piastów Slaskich we WroclawiuWayne State UniversityCentre hospitalier universitaire Sainte-JustineUniversità Cattolica del Sacro CuoreUniversity of WashingtonEberhard Karls Universität TübingenUniversitätsklinikum ErlangenEuropean CommissionTechnische Universität DresdenUniwersytet WarszawskiUniversity College London
KeywordsMedicineHypoxic Ischemic EncephalopathyRandomized controlled trialHypothermiaPopulationEncephalopathyPlaceboAllopurinolClinical endpointNeurocognitivePediatricsAnesthesiaInternal medicinePsychiatryPathologyCognition

Abstract

fetched live from OpenAlex

BACKGROUND: Despite therapeutic hypothermia (TH) and neonatal intensive care, 45-50% of children affected by moderate-to-severe neonatal hypoxic-ischemic encephalopathy (HIE) die or suffer from long-term neurodevelopmental impairment. Additional neuroprotective therapies are sought, besides TH, to further improve the outcome of affected infants. Allopurinol - a xanthine oxidase inhibitor - reduced the production of oxygen radicals and subsequent brain damage in pre-clinical and preliminary human studies of cerebral ischemia and reperfusion, if administered before or early after the insult. This ALBINO trial aims to evaluate the efficacy and safety of allopurinol administered immediately after birth to (near-)term infants with early signs of HIE. METHODS/DESIGN: The ALBINO trial is an investigator-initiated, randomized, placebo-controlled, double-blinded, multi-national parallel group comparison for superiority investigating the effect of allopurinol in (near-)term infants with neonatal HIE. Primary endpoint is long-term outcome determined as survival with neurodevelopmental impairment versus death versus non-impaired survival at 2 years. RESULTS: The primary analysis with three mutually exclusive responses (healthy, death, composite outcome for impairment) will be on the intention-to-treat (ITT) population by a generalized logits model according to Bishop, Fienberg, Holland (Bishop YF, Discrete Multivariate Analysis: Therory and Practice, 1975) and ."will be stratified for the two treatment groups. DISCUSSION: The statistical analysis for the ALBINO study was defined in detail in the study protocol and implemented in this statistical analysis plan published prior to any data analysis. This is in accordance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. TRIAL REGISTRATION: ClinicalTrials.gov NCT03162653. Registered on 22 May 2017.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.055
metaresearch head score (Gemma)0.109
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Protocol · Consensus signal: Protocol
Teacher disagreement score0.202
Threshold uncertainty score0.674

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0550.109
Meta-epidemiology (narrow)0.0030.002
Meta-epidemiology (broad)0.0050.006
Bibliometrics0.0030.003
Science and technology studies0.0010.003
Scholarly communication0.0030.002
Open science0.0020.002
Research integrity0.0030.008
Insufficient payload (model declined to judge)0.2020.021

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.072
GPT teacher head0.417
Teacher spread0.345 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreProtocol

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations11
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueTrialsSame topicNeonatal and fetal brain pathologyFrench-language works237,207